文献速递乳腺癌放疗泌尿生殖与妇科肿瘤放疗放疗物理与技术

2015至2019年乳腺癌与前列腺癌短程放疗利用趋势及Medicare支出:基于治疗周期的分析

Trends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-12-08

该回顾性队列分析纳入2015至2019年Medicare中143729例乳腺癌和114214例前列腺癌外照射放疗周期,评估短程放疗使用趋势与支出差异。乳腺癌短程放疗占44.27%,前列腺癌占22.72%;乳腺癌短程放疗中位总支出9418美元低于长程放疗的13602美元。短程放疗与较年长及医院附属机构治疗相关。

要点

  • 乳腺癌短程放疗占44.27%,前列腺癌短程放疗占22.72%。
  • 乳腺癌短程放疗中位总支出9418美元,低于长程放疗的13602美元。
  • 短程放疗与较年长及医院附属机构治疗相关(P < .001)。

核心结论

  • 在2015至2019年乳腺癌和前列腺癌放疗周期评估中,短程放疗比长程放疗费用更低。
  • 短程放疗在医院附属机构更常见。

研究设计与样本

  • 回顾性队列分析,纳入2015至2019年所有乳腺癌和前列腺癌外照射放疗周期,共143729例乳腺癌周期和114214例前列腺癌周期。
  • 采用多变量逻辑回归分析短程放疗接受率的调整比值比,采用多变量线性回归评估Medicare支出。

主要发现

  • 乳腺癌周期中短程放疗为63623例(44.27%),前列腺癌周期中短程放疗为25955例(22.72%)。
  • 乳腺癌短程放疗中位总支出9418美元(四分位距7966至10983美元),长程放疗为13602美元(四分位距11814至15499美元)。
  • 前列腺癌立体定向体部放疗中位总支出6924美元(四分位距4509至12905美元),中度大分割为18768美元(四分位距15421至20740美元),长程放疗为27319美元(四分位距25446至29421美元)。
  • 逻辑回归显示,乳腺癌和前列腺癌周期中接受短程放疗均与较年长相关,且与在自由站立机构相比在医院附属机构治疗相关(所有P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evidence supports the value of shorter, similarly efficacious, and potentially more cost-effective hypofractionated radiation therapy (RT) regimens in many clinical scenarios for breast cancer (BC) and prostate cancer (PC). However, practice patterns vary considerably. We used the most recent Centers for Medicare and Medicaid Services data to assess trends in RT cost and practice patterns among episodes of BC and PC. METHODS AND MATERIALS: We performed a retrospective cohort analysis of all external beam RT episodes for BC and PC from 2015 to 2019 to assess predictors of short-course RT (SCRT) use and calculated spending differences. Multivariable logistic regression defined adjusted odds ratios of receipt of SCRT over longer-course RT (LCRT) by treatment modality, age, year of diagnosis, type of practice, and the interaction between year and treatment setting. Medicare spending was evaluated using multivariable linear regression controlling for duration of RT regimen (SCRT vs LCRT) in addition to the above covariables. RESULTS: Of 143,729 BC episodes and 114,214 PC episodes, 63,623 (44.27%) and 25,955 (22.72%) were SCRT regimens, respectively. Median total spending for SCRT regimens among BC episodes was $9418 (interquartile range [IQR], $7966-$10,983) versus $13,602 (IQR, $11,814-$15,499) for LCRT. Among PC episodes, median total spending was $6924 (IQR, $4,509-$12,905) for stereotactic body RT, $18,768 (IQR, $15,421-$20,740) for moderate hypofractionation, and $27,319 (IQR, $25,446-$29,421) for LCRT. On logistic regression, receipt of SCRT was associated with older age among both BC and PC episodes as well as treatment at hospital-affiliated over freestanding sites (P < .001 for all). CONCLUSIONS: In this evaluation of BC and PC RT episodes from 2015 to 2019, we found that shorter-course RT resulted in lower costs than longer-course RT. SCRT was also more common in hospital-affiliated sites. Future research focusing on potential payment incentives encouraging SCRT when clinically appropriate in the 2 most common cancers treated with RT will be valuable as the field continues to prospectively evaluate cost-effective hypofractionation in other disease sites.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Patel TA, Jain B, Vapiwala N, et al. Trends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019. Int J Radiat Oncol Biol Phys. 2023. PMID: 38072324. doi:10.1016/j.ijrobp.2023.11.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。